Biscayne Pharmaceuticals
4770 Biscayne Boulevard
Suite 660
Miami
Florida
33137
United States
Tel: 786-502-4220
Website: http://biscaynepharma.com/
Email: info@biscaynepharma.com
12 articles about Biscayne Pharmaceuticals
-
Biscayne Pharma Readies Phase Ib Trial For Novel Antiepileptic Agent BIS-001 And Receives FDA Orphan Drug Designation For Dravet Syndrome
5/9/2017
-
Biscayne Pharma Forms Biscayne Neurotherapeutics and Completes $3 Million Series B Funding Round
1/27/2017
-
Newly Published Data Show Biscayne Pharmaceuticals' Novel Antiepileptic Drug Can Eliminate Seizures In Models Of Dravet Syndrome
10/24/2016
-
Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 At Eilat Conference On New Antiepileptic Drugs
6/28/2016
-
Biscayne Pharmaceuticals Presents Data At 2015 American Epilepsy Society Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug
12/7/2015
-
Biscayne Pharmaceuticals Release: New Study Published In PNAS Shows Biscayne's GHRH Agonists Could Increase The Feasiblity Of Beta Cell Transplants To Treat Type 1 Diabetes
10/20/2015
-
Biscayne Pharmaceuticals Merges With Insero Health, Adding Clinical-Stage Novel Epilepsy Program And Other CNS Assets
10/5/2015
-
ASCO15: Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes
5/28/2015
-
Biscayne Pharmaceuticals Presents Data At 2014 San Antonio Breast Cancer Symposium Further Confirming The Relevance Of Its GHRH Target In Cancer
12/9/2014
-
Biscayne Pharmaceuticals Presents Data At 2014 San Antonio Breast Cancer Symposium Further Confirming The Relevance Of Its GHRH Target In Cancer
12/9/2014
-
Data Presented At Breast Cancer Symposium 2014 Validates Biscayne Pharmaceuticals' GHRH Target In Breast Cancer
9/3/2014
-
Biscayne Pharmaceuticals' GHRH Technology Featured In Presentations At International Society For Heart Research Meeting
5/14/2014